No hay productos en el carro de la compra
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Casa > IL-2


Brief Information

Target Synonym:T-cell growth factor,IL2,Interleukin 2,T Cell Growth Factor,Aldesleukin,IL-2,TCGF,Involved In Regulation Of T-Cell Clonal Expansion,Interleukin-2,Lymphokine
Number of Launched Drugs:1
Number of Drugs in Clinical Trials:31
Lastest Research Phase:Approved

Product ListCompare or Buy

ACRO Quality

Part of Bioactivity data

GMP-L02H14-Cell-based assay

GMP Human IL-2 Protein (Cat. No. GMP-L02H14) stimulates proliferation of CTLL-2 cells. The specific activity of GMP Human IL-2 is ≥1.2*10^7 IU/mg, which is calibrated against human Interleukin-2 China National Standard (NIFDC code: 270008) (QC tested). China National Institutes for Food and Drug Control (NIFDC) Standard was prepared and calibrated against human IL-2 WHO International Standard (NIBSC code: 86/500) by NIFDC.

IL2-H5215-Cell-based assay

Human IL-2 Protein, premium grade (Cat. No. IL2-H5215) stimulates proliferation of CTLL-2 cells. The specific activity of Human IL-2 Protein, premium grade is >5.00 ⅹ 10^6 IU/mg, which is calibrated against Interleukin-2 (Human, rDNA derived) (2nd International Standard) (NIBSC code: 86/500) (QC tested).


Cynomolgus IL-2 R beta, His Tag (Cat. No. ILB-C52H9) immobilized on CM5 Chip can bind Cynomolgus IL-2, His Tag (Cat. No. IL2-C5249) with an affinity constant of 377 nM as determined in a SPR assay (Biacore 8K) (Routinely tested).


Mouse IL-2, His Tag (Cat. No. IL2-M52H3) immobilized on CM5 Chip can bind Mouse IL-2 R beta, Fc Tag (Cat. No. ILB-M5253) with an affinity constant of 36.2 μM as determined in a SPR assay (Biacore 8K) (Routinely tested).

Customer Reviews

Synonym Name

IL2,TCGF,lymphokine,Interleukin 2


Interleukin-2 (IL-2) is an interleukin, a type of cytokine immune system signaling molecule, which is a leukocytotrophic hormone that is instrumental in the body's natural response to microbial infection and in discriminating between foreign (non-self) and self. IL-2 mediates its effects by binding to IL-2 receptors, which are expressed by lymphocytes, the cells that are responsible for immunity. Mature human IL-2 shares 56% and 66% aa sequence identity with mouse and rat IL-2, respectively. Human and mouse IL-2 exhibit crossspecies activity. The receptor for IL-2 consists of three subunits that are present on the cell surface in varying preformed complexes. IL-2 is also necessary during T cell development in the thymus for the maturation of a unique subset of T cells that are termed regulatory T cells (T-regs). After exiting from the thymus, T-Regs function to prevent other T cells from recognizing and reacting against "self antigens", which could result in "autoimmunity". T-Regs do so by preventing the responding cells from producing IL-2. Thus, IL-2 is required to discriminate between self and non-self, another one of the unique characteristics of the immune system.

Clinical and Translational Updates

Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Thalidomide NSC-66847; NSC-527179; K-17; VP-02; FPF-300; FPF300 Approved Celgene Corp Talizer, Thalidomide Celgene, Thalidomide Pharmion, Synovir, Thalomid, Thaled Mainland China Leprosy, Lepromatous; Multiple Myeloma Changzhou Pharmaceutical Factory 1982-01-01 Lymphoma, Mantle-Cell; Leprosy, Lepromatous; Colorectal Neoplasms; Neuroectodermal Tumors, Primitive; Prostatitis; Primary Myelofibrosis; Adenocarcinoma, Clear Cell; Lymphoma, Follicular; Carcinoma, Adenosquamous; Cholangitis, Sclerosing; Osteosarcoma; Endometrial Neoplasms; Xerostomia; Gastrointestinal Hemorrhage; Sarcoma, Ewing; HIV Wasting Syndrome; Pancreatitis, Chronic; Arachnoiditis; Retinoblastoma; Erythema Nodosum; Prostatic Neoplasms; Drug Resistant Epilepsy; Leukemia, Lymphocytic, Chronic, B-Cell; Vascular Malformations; Myelodysplastic-Myeloproliferative Diseases; Stomatitis; Burning Mouth Syndrome; Mycobacterium avium-intracellulare Infection; Amyotrophic Lateral Sclerosis; Neoplasm Metastasis; Carcinoma, Hepatocellular; Melanoma; Sarcoma; Angiodysplasia; Lymphoma, Non-Hodgkin; Appendiceal Neoplasms; Pelvic Pain; Waldenstrom Macroglobulinemia; Glioma; Uterine Neoplasms; Anemia, Sideroblastic; Lung Neoplasms; Mycobacterium Infections; Lupus Erythematosus, Discoid; Anemia, Refractory, with Excess of Details

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
DF-6215 DF6215; DF-6215 Phase 1 Clinical Dragonfly Therapeutics Llc Solid tumours Details
VIS171 VIS-171; VIS171 Phase 1 Clinical Visterra Inc Autoimmune Diseases Details
SHR-1916 SHR-1916 Phase 1 Clinical Jiangsu Hengrui Medicine Co Ltd Solid tumours Details
RG-6279 RG-6279 Phase 1 Clinical F. Hoffmann-La Roche Ltd Solid tumours Details
SAR-444336 SAR-444336 Phase 1 Clinical Sanofi Inflammation Details
STK-012 STK-012 Phase 1 Clinical Synthekine Inc Solid tumours; Mismatch Repair Deficient Cancer; Stomach Neoplasms; Squamous Cell Carcinoma of Head and Neck; Esophageal Neoplasms; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Microsatellite instability-high cancer; Uterine Cervical Neoplasms; Melanoma; Carcinoma, Non-Small-Cell Lung Details
AB-248 AB-248 Phase 1 Clinical Asher Biotherapeutics Inc Solid tumours; Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Melanoma; Carcinoma, Non-Small-Cell Lung Details
SIM-0278 ALM-223; SIM0278 Phase 1 Clinical Simcere Pharmaceutical Group Ltd Autoimmune Diseases; Lupus Erythematosus, Systemic; Dermatitis, Atopic Details
M5A-IL2 Immunocytokine M5A-ICK Phase 1 Clinical National Cancer Institute, City Of Hope National Medical Center Breast Neoplasms; Colorectal Neoplasms Details
Interleukin-2 gene therapy (St Jude Children's Research Hospital) Phase 1 Clinical St Jude Children's Research Hospital, National Cancer Institute Neuroblastoma Details
Bifikafusp alfa L19-IL-2 Phase 3 Clinical Philogen Spa Solid tumours; Melanoma; Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis Details
Igrelimogene litadenorepvec PM-1016; PM1016; TILT-123 Phase 1 Clinical Tilt Biotherapeutics Ltd Solid tumours; Ovarian Neoplasms; Squamous Cell Carcinoma of Head and Neck; Peritoneal Neoplasms; Lung Neoplasms; Fallopian Tube Neoplasms; Melanoma; Carcinoma, Hepatocellular Details
attIL2-T cell therapy Phase 1 Clinical The University Of Texas MD Anderson Cancer Center Soft Tissue Neoplasms; Osteosarcoma; Sarcoma Details
Dodekin Phase 1 Clinical Philogen Spa Solid tumours; Neoplasm Metastasis Details
T20K T-20K Phase 1 Clinical Cyxone Multiple Sclerosis Details
XTX-202 XTX-202 Phase 2 Clinical Xilio Development Inc, Xilio Therapeutics Inc Solid tumours; Carcinoma, Renal Cell; Melanoma Details
ASP-1012 VET2-L2; ASP-1012; ASP1012 Phase 1 Clinical KaliVir Immunotherapeutics Inc Solid tumours Details
AVB-001 AVB-001 Phase 2 Clinical Avenge Bio Inc Ovarian Neoplasms; Peritoneal Neoplasms; Fallopian Tube Neoplasms Details
S-95007 S-95007 Phase 2 Clinical Laboratoires Servier Immune System Diseases; Inflammation Details
Darleukin/fibromun L19-IL-2/ L19-TNF-α Phase 3 Clinical Philogen Spa Carcinoma, Merkel Cell; Carcinoma, Basal Cell; Carcinoma, Skin Appendage; Keratoacanthoma; Basal Cell Nevus Syndrome; Carcinoma, Squamous Cell; Lymphoma, T-Cell, Cutaneous; Melanoma; Sarcoma, Kaposi Details
KB-707 KB-707; KB707 Phase 1 Clinical Krystal Biotech Inc Skin Melanoma; Carcinoma, Basal Cell; Neoplasms; Osteosarcoma; Carcinoma, Squamous Cell; Melanoma Details
Saltikva Phase 2 Clinical Salspera LLC Pancreatic Neoplasms Details
AU-007 BD-8; AU-007; BDG-8 Phase 2 Clinical Biolojic Design Inc Solid tumours; Neoplasms; Neoplasm Metastasis Details
KY-0118 KY-0118; KY0118 Phase 1 Clinical Novatim Immune Therapeutics (Zhejiang) Co Ltd Solid tumours; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Neoplasms; Pancreatic Neoplasms; Colorectal Neoplasms; Melanoma; Carcinoma, Non-Small-Cell Lung Details
umitrelimorgene autodencel ITI-1000 Phase 2 Clinical Immunomic Therapeutics Inc Glioblastoma Details
MK-1484 MK-1484; SP-482 Phase 1 Clinical Merck & Co Inc, Sutro Biopharma Inc Solid tumours Details
BNT-153 BNT-153 Phase 1 Clinical Biontech Se Solid tumours Details
RS-2102 RS2102 Phase 1 Clinical Reistone Biopharma Co Ltd Dermatitis, Atopic Details
LMBP2-specific TCR-T cell therapy (TCRCure Biopharma) Phase 2 Clinical Tcrcure Biopharma Ltd Nasopharyngeal Carcinoma Details
Mableukin 2PD1(Anwita Biosciences) AWT020; AWT-020 Phase 1 Clinical Anwita Biosciences Inc Neoplasms; Autoimmune Diseases of the Nervous System Details
BNZ-1 BNZ132-1-40; BNZ-1; BNZ132-1; BNZ-01; EQ101; EQ-101 Phase 2 Clinical Bioniz Therapeutics Inc Alopecia; Alopecia Areata; Lymphoma, T-Cell, Cutaneous; Leukemia, Large Granular Lymphocytic Details

This web search service is supported by Google Inc.

Call us
Call us
North America:
+1 800-810-0816 (Toll Free)
Asia & Pacific:
+86 400-682-2521
Correo electrónico
+1 888-377-6111
Lichtstrasse 35,4056 Basel, Switzerland

Dejar un mensaje